Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4228-4233

  Oostendorp, Roos L ^a,d   Huitema, Alwin ^b   Rosing, Hilde ^b   Jansen, Robert S ^b   Heine, Rob Ter ^b   Keessen, Marianne ^a   Beijnen, Jos H ^b,c   Schellens, Jan H M ^a,c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; GLYCOPROTEIN P; GRANISETRON; RITONAVIR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DOSE SEQUENCE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART CARCINOMA; HICCUP; HUMAN; HYPERKALEMIA; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PENIS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; COHORT STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; RITONAVIR; TAXOIDS;

EID: 67549142429     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2944     Document Type: Article

References (26)

1. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-2567 (Pubitemid 28309055)
2. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115 (Pubitemid 27021524)
3. Schellens JH, Malingre MM, Kruijtzer CM, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000;12:103-110 (Pubitemid 30847541)
4. Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168 (Pubitemid 28265054)
5. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-1365 (Pubitemid 39295024)
6. Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25:1377-1382 (Pubitemid 46706885)
7. Wils P, Phung-Ba V, Warnery A, et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 1994;48:1528-1530 (Pubitemid 24318161)
8. van Asperen J, van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997;76:1181-1183 (Pubitemid 27448014)
9. Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:1160-1166 (Pubitemid 32176294)
10. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56:1296-1302 (Pubitemid 26080972)
11. Shou M, Martinet M, Korzekwa KR, et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998;8:391-401. (Pubitemid 28475303)
12. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-6164 (Pubitemid 35244466)
13. Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 Protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004;64:7426-7431 (Pubitemid 39372084)
14. Huisman MT, Smit JW, Wiltshire HR, et al. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001;59:806-813 (Pubitemid 32274009)
15. Kharasch ED, Bedynek PS, Walker A, et al. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 2008.
16. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-660 (Pubitemid 27098420)
17. Kappelhoff BS, Huitema AD, Sankatsing SU, et al. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005;60:276-286 (Pubitemid 41224135)
18. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117:3583-3592 (Pubitemid 350097013)
19. Kuppens IE, van Maanen MJ, Rosing H, et al. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005;19:355-361 (Pubitemid 40990725)
20. ter Heine R, Alderden-Los CG, Rosing H, et al. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drugmonitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:2505-2514
21. Wang H, Huang H, Li H, et al. Activated pregnenolone X-receptor is a target for ketoconazole and its analog. Clin Cancer Res 2007;13:2488-2495 (Pubitemid 46698601)
22. Huang H, Wang H, Sinz M, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007;26:258-268 (Pubitemid 46095736)
23. Kiyotani K, Mushiroda T, Kubo M, et al. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008;99:967-972 (Pubitemid 351997599)
24. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996;60:601-607 (Pubitemid 27025907)
25. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85:64-70.
26. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8:161-170 (Pubitemid 28041013)